Strs Ohio boosted its holdings in shares of Globus Medical Inc (NYSE:GMED) by 275.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,700 shares of the medical device company’s stock after purchasing an additional 26,200 shares during the quarter. Strs Ohio’s holdings in Globus Medical were worth $1,467,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its position in shares of Globus Medical by 12.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 390,522 shares of the medical device company’s stock worth $16,051,000 after acquiring an additional 43,747 shares during the period. Marathon Asset Management LLP lifted its position in shares of Globus Medical by 1.6% in the 4th quarter. Marathon Asset Management LLP now owns 771,826 shares of the medical device company’s stock worth $31,722,000 after acquiring an additional 12,126 shares during the period. Thomson Horstmann & Bryant Inc. bought a new stake in shares of Globus Medical in the 4th quarter worth approximately $480,000. RK Asset Management LLC lifted its position in shares of Globus Medical by 3.9% in the 4th quarter. RK Asset Management LLC now owns 109,946 shares of the medical device company’s stock worth $4,519,000 after acquiring an additional 4,135 shares during the period. Finally, Atlantic Trust Group LLC bought a new stake in shares of Globus Medical in the 3rd quarter worth approximately $1,110,000. Hedge funds and other institutional investors own 70.03% of the company’s stock.

In related news, insider A Brett Murphy sold 51,449 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the completion of the transaction, the insider now owns 49,768 shares in the company, valued at approximately $1,741,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David D. Davidar sold 55,383 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $40.66, for a total value of $2,251,872.78. Following the transaction, the director now owns 752,236 shares of the company’s stock, valued at approximately $30,585,915.76. The disclosure for this sale can be found here. Insiders have sold a total of 124,908 shares of company stock valued at $4,747,975 in the last 90 days. 28.21% of the stock is owned by corporate insiders.

GMED has been the subject of a number of research reports. BidaskClub upgraded Globus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, October 7th. Barclays reduced their price objective on Globus Medical from $28.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, October 19th. Piper Jaffray Companies reiterated a “buy” rating on shares of Globus Medical in a research report on Thursday, October 19th. BTIG Research reiterated a “buy” rating and issued a $37.00 price objective on shares of Globus Medical in a research report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. Globus Medical presently has an average rating of “Buy” and an average price target of $40.57.

Globus Medical Inc (GMED) opened at $45.64 on Friday. The company has a market capitalization of $4,398.60, a P/E ratio of 36.51, a P/E/G ratio of 2.67 and a beta of 0.48. Globus Medical Inc has a 52-week low of $25.85 and a 52-week high of $47.09.

Globus Medical (NYSE:GMED) last posted its earnings results on Wednesday, November 8th. The medical device company reported $0.30 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.30. The business had revenue of $151.74 million during the quarter, compared to the consensus estimate of $150.73 million. Globus Medical had a return on equity of 13.67% and a net margin of 17.54%. Globus Medical’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. equities analysts forecast that Globus Medical Inc will post 1.28 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Globus Medical Inc (GMED) Position Increased by Strs Ohio” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/04/globus-medical-inc-gmed-position-increased-by-strs-ohio.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.